Streamlining Anthem (Elevance Health) Xultophy Prior Authorization

Understanding Xultophy Prior Authorization with Anthem (Elevance Health)

Xultophy is an injectable medication prescribed for adults with type 2 diabetes to improve glycemic control. As a high-volume prior authorization target, its approval process with Anthem-licensed plans across various states and lines of business necessitates a clear understanding of payer-specific requirements and submission pathways.

Anthem Xultophy Prior Authorization Submission Channels

• For retail pharmacy benefit Xultophy, prior authorizations are typically managed by CarelonRx, Elevance Health's in-house PBM. Submissions can be made through CarelonRx's provider PA system or via ePA partners like CoverMyMeds and Surescripts.
• While Xultophy is primarily a pharmacy benefit drug, if administered under a medical benefit scenario (e.g., specific clinic-administered programs), submissions would route through Availity Essentials, Anthem's primary multi-payer provider workspace. X12 278 transactions are also supported via clearinghouses.

Accessing Anthem Medical Policies for Xultophy

Anthem operating companies publish their medical policies and clinical utilization management guidelines through provider sites, typically accessed via Availity. For Xultophy, relevant criteria will be found within these state-specific medical policy libraries, which align with the broader Elevance Health corporate criteria framework. Always verify the specific policy number, plan-state context, and effective date.

Typical Xultophy Prior Authorization Denial Patterns from Anthem

• Medical necessity or insufficient documentation: Lack of clinical detail supporting Xultophy use or failure to meet specific criteria.
• Failure to complete step therapy: Xultophy often has step therapy requirements, necessitating trials of other diabetes medications first.
• Non-formulary status: The specific Anthem plan's formulary may not cover Xultophy or may require an exception process.
• Quantity limits exceeded: If the prescribed dosage exceeds plan limits without adequate clinical justification.

Anthem's Appeal Process for Xultophy Prior Authorization Denials

Denials for Xultophy prior authorizations are returned via X12 277/835 transactions and through Availity status updates. The standard appeal pathway for medical and pharmacy benefit denials routes through the Anthem operating company's appeals process as documented in their provider manual. Peer-to-peer reviews are generally available as part of this process.

Automating Anthem Xultophy Prior Authorizations with Klivira

Klivira integrates directly with EMRs and payer portals, including Anthem's submission channels, to automate the Xultophy prior authorization workflow. Our platform streamlines data extraction, submission, status tracking, and documentation management, significantly reducing manual effort and potential delays across commercial, Medicare Advantage, and Medicaid lines of business.